1. Search Result
Search Result
Results for "

μ

" in MedChemExpress (MCE) Product Catalog:

227

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

1

Biochemical Assay Reagents

58

Peptides

25

Natural
Products

12

Recombinant Proteins

4

Isotope-Labeled Compounds

9

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155319

    Opioid Receptor Neurological Disease
    μ opioid receptor agonist 3 (compound 20) is a potent μ opioid receptor (µOR) agonist with an EC50 of 0.87 nM. μ opioid receptor agonist 3 has the potential for pain and neuropsychiatric indications research .
    μ opioid receptor agonist 3
  • HY-P5790

    Sodium Channel Neurological Disease
    μ-TRTX-Hd1a, a spider venom, is a selective NaV 1.7 inhibitor. μ-TRTX-Hd1a is a gating modifier that inhibits human NaV 1.7 by interacting with the S3b-S4 paddle motif in channel domain II .
    μ-TRTX-Hd1a
  • HY-P10203

    Opioid Receptor Inflammation/Immunology
    μ/κ/δ opioid receptor agonist 1 is a μ opioid receptor (MOR), κ opioid receptor (KOR), and δ opioid receptor (DOR) agonist. μ/κ/δ opioid receptor agonist 1 produces a strong and long-lasting analgesic effect through peripheral MOR and KOR in the tail-flick test .
    μ/κ/δ opioid receptor agonist 1
  • HY-E70197

    μ-Calpain

    Cathepsin Others
    Calpain-1 (pig) (μ-Calpain) is an intracellular Ca 2+-regulated cysteine protease. Calpain-1 (pig) exhibits neuroprotective effect .
    Calpain-1 (pig)
  • HY-P5809

    μ-TrTx-Pe1b

    Sodium Channel Neurological Disease
    Pe1b (μ-TrTx-Pe1b) is a selective Nav1.7 inhibitor with an IC50 of 167 nM .
    Pe1b
  • HY-142919

    Opioid Receptor Neurological Disease
    μ opioid receptor agonist 2 (Compound H-3)is an optically pure oxaspiro ring substituted pyrrolopyrazole derivative, acts as a MOR receptor agonist and can be used for the research of pain and pain related diseases .
    μ opioid receptor agonist 2
  • HY-142918

    Opioid Receptor Neurological Disease
    μ opioid receptor agonist 1 (Compound H-1a)is an optically pure oxaspiro ring substituted pyrrolopyrazole derivative, acts as a MOR receptor agonist and can be used for the research of pain and pain related diseases .
    μ opioid receptor agonist 1
  • HY-P5801

    μ-TrTx-Phlo1a

    Sodium Channel Neurological Disease
    Phlo1a (μ-TrTx-Phlo1a) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective Nav1.7 inhibitor. Phlo1a has a weak inhibitory effect on Nav1.2 and Nav1.5 .
    Phlo1a
  • HY-P5800

    μ-TrTx-Phlo1b

    Sodium Channel Neurological Disease
    Phlo1b (μ-TrTx-Phlo1b) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective Nav1.7 inhibitor. Phlo1b has a weak inhibitory effect on Nav1.2 and Nav1.5 .
    Phlo1b
  • HY-P5153

    μ-TRTX-Tp1a

    Sodium Channel Neurological Disease
    ProTx-III is a selective and potent inhibitor of voltage-gated sodium channel Nav1.7, with an IC50 of 2.1 nM. ProTx-III is a spider venom peptide isolated from the venom of the Peruvian green velvet tarantella. ProTx-III has a typical inhibitor cystine knot motif (ICK). ProTx-III is able to reverse the pain response. ProTx-III can be used to study diseases such as chronic pain, epilepsy, and arrhythmia .
    ProTx-III
  • HY-144609

    Opioid Receptor Neurological Disease
    Mu opioid receptor antagonist 4 (compound 31) is a potent and selective μ opioid receptor (MOR) antagonist with a Ki of 0.38 nM and an EC50 of 1.07 nM. Mu opioid receptor antagonist 4 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Mu opioid receptor antagonist 4 Mu opioid receptor antagonist 4 can be used for researching opioid use disorders (OUD) .
    Mu opioid receptor antagonist 4
  • HY-144608

    Opioid Receptor Neurological Disease
    Mu opioid receptor antagonist 3 (compound 26) is a potent and selective μ opioid receptor (MOR) antagonist with a Ki of 0.24 nM and an EC50 of 0.54 nM. Mu opioid receptor antagonist 3 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Mu opioid receptor antagonist 3 can be used for researching opioid use disorders (OUD) .
    Mu opioid receptor antagonist 3
  • HY-144610

    Opioid Receptor Neurological Disease
    Mu opioid receptor antagonist 5 (compound NAP) is a selective and blood-brain barrier (BBB) penetrant μ opioid receptor (MOR) antagonist with an EC50 value of 1.14 nM and a Ki value of 0.37 nM. Mu opioid receptor antagonist 5 can be used for researching opioid use disorders (OUD) .
    Mu opioid receptor antagonist 5
  • HY-144607

    Opioid Receptor Neurological Disease
    Mu opioid receptor antagonist 2 (compound 25) is a potent, selective and blood-brain barrier (BBB) penetrant μ opioid receptor (MOR) antagonist with a Ki of 0.37 nM and an EC50 of 0.44 nM. Mu opioid receptor antagonist 2 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Mu opioid receptor antagonist 2 can be used for researching opioid use disorders (OUD) .
    Mu opioid receptor antagonist 2
  • HY-147560

    Sigma Receptor Opioid Receptor Neurological Disease
    σ1 Receptor/μ Opioid receptor modulator 1 (Compound 44) is a potent σ1 receptor antagonist and μ opioid receptor agonist with Kis of 1.86 nM and 2.1 nM, respectively.σ1 Receptor/μ Opioid receptor modulator 1 exhibits potent analgesic activity. σ1 Receptor/μ Opioid receptor modulator 1 can be used for the research of neuropathic pain .
    σ1 Receptor/μ Opioid receptor modulator 1
  • HY-D1632

    Fluorescent Dye Others
    4-MU-α-GlcNS sodium is a fluorogenic substrate of heparin sulphamidase, is desulfurized into 4-MU-α-GlcNH2. 4-MU-α-GlcNH2 can liberate 4-methylumbelliferone (4-MU, fluorescent product) via α-glucosaminidase catalysis, with the emission wavelength maxima of 445-454 nm. 4-MU-α-GlcNS sodium can be used to heparin sulphamidase deficiencies associated with Mucopolisaccaridosis IIIA and other lysosomal disorders researches .
    4-MU-α-GlcNS sodium
  • HY-145813

    Histone Methyltransferase Cancer
    MU1656 is a potent and selective inhibitor of histone methyltransferase DOT1L, with an IC50 of 2 nM. MU1656 can be used for the research of hematological malignancies .
    MU1656
  • HY-148246

    TGF-β Receptor Cancer
    MU1700 is an orally active and potent ALK1/2 inhibitor with IC50s of 13 nM and 6 nM, respectively. MU1700 shows cell membrane permeability and high brain permeability .
    MU1700
  • HY-170845

    Endonuclease Cancer
    MU1409 is an inhibitor of MRE11 nuclease with an IC50 of 12.1 μM. Additionally, MU1409 also inhibits FEN1 and EXO1, with IC50 values of 24.2 and 176.4 μM, respectively. MU1409 affects DNA repair in cells, preventing the degradation of stalled replication forks in BRCA2-deficient cells, making it a promising candidate for research on BRCA2 mutation-induced cancers .
    MU1409
  • HY-170844

    Endonuclease Cancer
    MU147 is an MRE11 nuclease inhibitor and chemical probe with anticancer activity, which is lethal to Ehrlich ascites tumor cells both in vitro and in vivo. MU147 also eliminates the double-strand break repair mechanism dependent on the MRE11 nuclease activity without impairing the activation of ATM. MU147 also impairs the degradation of nascent strands of stalled replication FOX and selectively affects brca2-deficient cells .
    MU147
  • HY-170546

    Haspin Kinase Cancer
    MU1920 is an ATP-competitive, selective inhibitor for haspin with an IC50 of 6 nM. MU1920 exhibits good pharmacokinetic properties and metabolic stability in mouse plasma and microsomes without obvious anticancer effects, which can be used for development of chemical probes .
    MU1920
  • HY-162771

    Opioid Receptor Neurological Disease
    Mu opioid receptor agonist 1 (compound 12) is a Mu opioid receptor agonist. Mu opioid receptor agonist 1 can be used in nervous system related research .
    Mu opioid receptor agonist 1
  • HY-145519

    Fluorescent Dye Neurological Disease
    Mu-6S-Palm-β-Glc is a fluorogenic substrate for palmitoyl-protein thioesterase (PPT). Mu-6S-Palm-β-Glc can be used for the research of neuronal ceroid lipofuscin disease in infants .
    Mu-6S-Palm-β-Glc
  • HY-162669

    Opioid Receptor Neurological Disease
    Mu opioid receptor antagonist 8 (368) is a μ-opioid receptor antagonist. Mu opioid receptor antagonist 8 (368) significantly inhibits met-enkephalin-induced µOR activation of Gi .
    Mu opioid receptor antagonist 8
  • HY-148251

    Casein Kinase Cancer
    MU1742 is a probe for CK1δ and CK1ε protein kinases .
    MU1742
  • HY-112927

    Checkpoint Kinase (Chk) Cancer
    MU380 is a potent and selective CHK1 inhibitor that induces apoptosis and has anticancer activity .
    MU380
  • HY-144606

    Opioid Receptor Neurological Disease
    Mu opioid receptor antagonist 1 (compound 19) is a selective and orally active μ opioid receptor (MOR) ligand with an Ki value of 0.58 nM and an EC50 of 1.15 nM. Orally administrating with Mu opioid receptor antagonist 1 increases intestinal motility during morphine-induced constipation. Mu opioid receptor antagonist 1 can be used for researching opioid-induced constipation (OIC) .
    Mu opioid receptor antagonist 1
  • HY-10940
    Pifithrin-μ
    10+ Cited Publications

    PFTμ; 2-Phenylethynesulfonamide

    MDM-2/p53 HSP Autophagy Neurological Disease Cancer
    Pifithrin-μ is an inhibitor of p53 and HSP70, with antitumor and neuroprotective activity.
    Pifithrin-μ
  • HY-125290

    CDK DYRK Cancer
    MU1210 (compound 12f) is an inhibitor of CDC-like kinases Clk1, Clk2, and Clk4 (with IC50 values of 8, 20, and 12 nM respectively), with IC50 for HIPK1 and DYRK2 are 187 and 1309 nM. MU1210 also has favorable pharmacokinetic characteristics (in mice, 10 mg/kg, intraperitoneal injection: Cmax=1.24 μM, T1/2=58 minutes; no acute toxicity observed) .
    MU1210
  • HY-P10175

    Opioid Receptor Neurological Disease
    Acetalin-1 (Ac-RFMWMK-NH2), a hexapeptide, is a μ opioid receptor antagonist with high affinity for μ and κ3 opioid receptor, weak affinity for κ1 receptors and no affinity for κ2 receptors .
    Acetalin-1
  • HY-155320

    Opioid Receptor Neurological Disease
    Mu opioid receptor antagonist 7 (compound 24) is a potent and CNS permeable antagonist of µOR (µ-opioid receptor), with an IC50 of 29 ± 3.0 nM. Mu opioid receptor antagonist 7 can be used for the research of pain and opioid use disorder .
    Mu opioid receptor antagonist 7
  • HY-19707
    4μ8C
    Maximum Cited Publications
    47 Publications Verification

    IRE1 Inhibitor III

    IRE1 Metabolic Disease
    4μ8C (IRE1 Inhibitor III) is a small-molecule inhibitor of IRE1α.
    4μ8C
  • HY-118135

    4MU-α-Gal

    Fluorescent Dye Others
    4-Methylumbelliferyl-α-D-galactopyranoside (4MU-α-Gal), a substrate for α-galactosidase A (GLA), is a blue pro-fluorogenic substrate. 4-Methylumbelliferyl-α-D-galactopyranoside forms two products, galactose and fluorescent 4MU, upon cleavage by GLA .
    4-Methylumbelliferyl-α-D-galactopyranoside
  • HY-P5989

    Mu-Val-HPh-FMK

    Antibiotic Infection
    Calpain inhibitor V (Mu-Val-HPh-FMK) is a cell-permeable and irreversible inhibitor of calpain that has anti-chlamydial activity .
    Calpain inhibitor V
  • HY-P1338

    Opioid Receptor Neurological Disease
    PL-017 is a potent and selective μ opioid receptor agonist with an IC50 of 5.5 nM for 125I-FK 33,824 binding to μ site. PL-017 produces long-lasting, reversible analgesia in rats .
    PL-017
  • HY-P1338A

    Opioid Receptor Neurological Disease
    PL-017 TFA is a potent and selective μ opioid receptor agonist with an IC50 of 5.5 nM for 125I-FK 33,824 binding to μ site. PL-017 TFA produces long-lasting, reversible analgesia in rats .
    PL-017 TFA
  • HY-163065

    Opioid Receptor Sigma Receptor Neurological Disease
    σ1 Receptor/μ Opioid receptor modulator 2 (compound 4x) is a dual μOR agonist/σ1R antagonist, and displays picomolar μOR agonism activity (EC50: 0.6 ± 0.2 nM) and good σ1R inhibitory activity (Ki: 363.7 ± 5.6 nM). σ1 Receptor/μ Opioid receptor modulator 2 exhibits robust analgesic effects in various pain models .
    σ1 Receptor/μ Opioid receptor modulator 2
  • HY-137873

    4-Methylumbelliferyl-α-D-Glucose; 4-Methylumbelliferyl-α-D-Glucoside; 4-MU-α-D-Glucopyranoside

    Fluorescent Dye Glycosidase Others
    4-Methylumbelliferyl-α-D-Glucopyranoside (4-Methylumbelliferyl-α-D-Glucose) is a fluorescent substrate for α-glucosidase, which releases the fluorescent moiety 4-methylumbelliferyl (4-MU) upon cleavage. 4-MU has pH-dependent fluorescence excitation activity, with excitation wavelengths of 320 nm at low pH (1.97-6.72) and 360 nm at high pH (7.12-10.3), respectively. The emission wavelength of 4-Methylumbelliferyl-α-D-Glucopyranoside increases with decreasing pH, ranging from 445-455 nm. 4-Methylumbelliferyl-α-D-Glucopyranoside can be used as a biomarker for Fabry and Pompe diseases to quantify α-glucosidase activity in infant blood spot samples.
    4-Methylumbelliferyl-α-D-Glucopyranoside
  • HY-101079

    Opioid Receptor Neurological Disease
    BRL 52537 hydrochloride is a highly selective κ-Opioid receptor (KOR) agonist with Kis of 0.24 nM and 1560 nM for κ and μ subtypes, respectively. BRL 52537 hydrochloride decreases ischemia-evoked NO production as a potential mechanism of neuroprotection. BRL 52537 hydrochloride attenuates early stroke damage .
    BRL 52537 hydrochloride
  • HY-P0210
    DAMGO
    5+ Cited Publications

    Opioid Receptor Cancer
    DAMGO is a μ-opioid receptor (μ-OPR ) selective agonist with a Kd of 3.46 nM for native μ-OPR .
    DAMGO
  • HY-P0210B
    DAMGO TFA
    5+ Cited Publications

    Opioid Receptor Cancer
    DAMGO TFA is a μ-opioid receptor (μ-OPR ) selective agonist with a Kd of 3.46 nM for native μ-OPR .
    DAMGO TFA
  • HY-P2018

    Opioid Receptor Cardiovascular Disease
    FK 33-824, a synthetic analogue of Met-enkephalin, is a selective agonist of the μ-opioid receptor (μ-OR) .
    FK 33-824
  • HY-137180

    Opioid Receptor Parasite Infection Neurological Disease
    Naloxonazine is a potent and selective opiate mu-1 antagonist that can also affect leishmania by regulating host coding function .
    Naloxonazine
  • HY-120927

    Opioid Receptor Neurological Disease
    Alvimopan metabolite is a μ opioid receptor antagonist with activity that selectively interacts with μ peripheral receptors. Alvimopan metabolite can be used as a potential inhibitory drug to alleviate the side effects caused by opioids. Alvimopan metabolite was identified as a highly selective μ opioid receptor antagonist during research and development .
    Alvimopan metabolite
  • HY-N0187
    4-Methylumbelliferone
    4 Publications Verification

    Hymecromone; 4-MU

    Others Cardiovascular Disease Cancer
    4-Methylumbelliferone is a hyaluronic acid biosynthesis inhibitor with antitumoral and antimetastatic effects.
    4-Methylumbelliferone
  • HY-101306

    Opioid Receptor Neurological Disease
    Clocinnamox (mesylate) is a potent opioid antagonist acting at mu, kappa and delta-receptors. Clocinnamox is a selective mu-receptor antagonist than kappa and delta-receptors .
    Clocinnamox mesylate
  • HY-W019823

    Fluorescent Dye Infection Neurological Disease
    4-MUNANA is a substrate of influenza virus neuraminidase (NA) with high selectivity and irreversible reaction. In the enzymatic reaction, 4-MUNANA is hydrolyzed by NA to generate fluorescent 4-methylumbelliferone (4-MU) . By detecting the fluorescence intensity of 4-MU, quantitative analysis of NA activity can be achieved. 4-MUNANA can be used in influenza-related research, such as screening NA inhibitors, developing new anti-influenza drugs, and studying the infection mechanism of influenza viruses .
    4-MUNANA
  • HY-123633

    Glycosidase Others
    4-Methylumbelliferyl β-D-Glucopyranoside, a β-D-glucoside, is a fluorogenic substrate for β-glucosidase, utilizes to assay β-glucosidase activity . 4-Methylumbelliferyl β-D-Glucopyranoside releases the highly fluorescent 4-methylumbelliferyl (4-MU), which has an emission maximum at 445-454 nm. The excitation maximum for 4-MU is pH-dependent: 330, 370, and 385 nm at pH 4.6, 7.4, and 10.4, respectively .
    4-Methylumbelliferyl β-D-Glucopyranoside
  • HY-156131

    ADL 2-1294

    Opioid Receptor Inflammation/Immunology
    Loperamide (ADL 2-1294) is a selective μ opioid receptor agonist with Kis of 3, 48 and 1156 nM against μ, δ and κ opioid receptor, respectively. Loperamide can be used as an antidiarrheal agent .
    Loperamide
  • HY-118416

    Opioid Receptor Neurological Disease
    BMS-986124 is a μ-opioid receptor silent allosteric modulator (μ-SAMs). BMS-986124 antagonizes positive allosteric modulator effect of BMS-986122 (µ-OR PAM) .
    BMS-986124

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: